---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002424"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:09:54.101606+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Kymera holds immunology R&D day; discloses new targets and clinical timelines

## Summary
- Company held virtual immunology R&D day on Jan 4, 2024, highlighting emerging pipeline.
- New target disclosures and supporting preclinical data presented.
- Clinical study initiation timing provided for immunology programs.
- No financial data or earnings guidance included in this filing.

## SEC filing metadata
- accession: 0001193125-24-002424
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524002424/0001193125-24-002424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524002424/d855441d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002424
- JSON: https://secwatch.observer/filing/0001193125-24-002424.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.